AHCO AdaptHealth Corp.

Nasdaq adapthealth.com


$ 10.67 $ 1.58 (17.38 %)    

Tuesday, 04-Nov-2025 16:52:19 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 10.67
$ 9.64
$ 9.34 x 2
$ 11.24 x 104
$ 9.53 - $ 10.68
$ 7.11 - $ 11.63
4,439,330
na
1.44B
$ 0.98
$ 17.57
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-25-2025 12-31-2024 10-K
5 11-05-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-07-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 03-06-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 07-31-2019 06-30-2019 10-Q
27 05-14-2019 03-31-2019 10-Q
28 03-29-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 adapthealth-affirms-fy2025-sales-guidance-of-3180b-3260b-vs-3225b-est

AdaptHealth (NASDAQ:AHCO) affirms FY2025 sales outlook from $3.180 billion-$3.260 billion to $3.180 billion-$3.260 billion vs $...

 adapthealth-q3-eps-016-misses-023-estimate-sales-820314m-beat-799311m-estimate

AdaptHealth (NASDAQ:AHCO) reported quarterly earnings of $0.16 per share which missed the analyst consensus estimate of $0.23 b...

 adapthealth-narrows-fy2025-sales-guidance-from-3150b-3290b-to-3180b-3260b-vs-3252b-est

Financial OutlookThe Company is updating previous financial guidance for fiscal year 2025, as follows:Net revenue of $3.18 bill...

 adapthealth-closes-disposition-of-certain-infusion-assets-in-wellness-at-home-segment-uses-sale-proceeds-to-pay-down-65m-in-debt

AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-center...

 truist-securities-maintains-buy-on-adapthealth-lowers-price-target-to-13

Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $1...

 rbc-capital-maintains-outperform-on-adapthealth-lowers-price-target-to-13

RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $14 t...

 adapthealth-lowers-fy2025-sales-guidance-from-322b-336b-to-318b-332b-vs-327b-est-sees-adjusted-ebitda-of-665m-to-705m-prior-670m-to-710m

Financial OutlookThe Company is updating previous financial guidance for fiscal year 2025 to account for the disposition of cer...

 adapthealth-q1-eps-005-misses-004-estimate-sales-77788m-beat-76477m-estimate

AdaptHealth (NASDAQ:AHCO) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.04 b...

 baird-maintains-outperform-on-adapthealth-raises-price-target-to-16

Baird analyst Eric Coldwell maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and raises the price target from $14 to $16.

 canaccord-genuity-maintains-buy-on-adapthealth-raises-price-target-to-14

Canaccord Genuity analyst Richard Close maintains AdaptHealth (NASDAQ:AHCO) with a Buy and raises the price target from $13 ...

 rbc-capital-maintains-outperform-on-adapthealth-raises-price-target-to-14

RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and raises the price target from $11 t...

 truist-securities-maintains-buy-on-adapthealth-raises-price-target-to-14

Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and raises the price target from $1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION